Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib and midostaurin may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth. Drugs used in chemotherapy, such as mitoxantrone
hydrochloride, etoposide, and cytarabine, work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Giving bortezomib and
midostaurin together with combination chemotherapy may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when
given together with midostaurin with or without combination chemotherapy in treating patients
with relapsed or refractory acute myeloid leukemia.